Trial Profile
Analysis of changes in adipose tissue of patients infected with HIV and lipoatrophy treated with nucleoside thymidine, after a switch to monotherapy with lopinavir/ritonavir [Analisis de Los Cambios en el Tejido Adiposo de Pacientes Con infeccion VIH y Lipoatrofia en Tratamiento Con analogos de nucleosidos timidinicos, Tras el Cambio a Monoterapia Con Lopinavir/Ritonavir]
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Lamivudine/zidovudine/abacavir
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms BIOKAL
- 10 Dec 2012 Status changed from suspended to discontinued.
- 10 Dec 2012 Status changed from recruiting to suspended.
- 11 Jul 2011 Planned end date changed from 1 Feb 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.